Black Diamond Therapeutics Inc (BDTX)vsInsmed Inc (INSM)
BDTX
Black Diamond Therapeutics Inc
$2.14
-0.47%
HEALTHCARE · Cap: $120.22M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 766% more annual revenue ($606.42M vs $70.00M). BDTX leads profitability with a 32.0% profit margin vs -2.1%. BDTX earns a higher WallStSmart Score of 63/100 (C+).
BDTX
Buy63
out of 100
Grade: C+
INSM
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+11.9%
Fair Value
$2.52
Current Price
$2.14
$0.38 discount
Intrinsic value data unavailable for INSM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 32 of every $100 in revenue as profit
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Strong operational efficiency at 28.4%
No standout strengths identified
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Negative free cash flow — burning cash
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BDTX
The strongest argument for BDTX centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 32.0% and operating margin at 28.4%.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : BDTX
The primary concerns for BDTX are Revenue Growth, EPS Growth, Market Cap.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
BDTX profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
BDTX carries more volatility with a beta of 3.43 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
BDTX generates stronger free cash flow (-7M), providing more financial flexibility.
Bottom Line
BDTX scores higher overall (63/100 vs 39/100), backed by strong 32.0% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Black Diamond Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Black Diamond Therapeutics, Inc., a biotechnology company, discovers and develops small molecule tumor agnostic therapies. The company is headquartered in Cambridge, Massachusetts.
Visit Website →Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?